BiologicMuscle & performance
- Primary research area
- Emerging research
- Regulatory status
- Research status varies
- Evidence level
- Evidence level not yet characterized
- Primary mechanism
- Mechanism not yet characterized
Study findings available · Coverage varies by sectionWhat has been observed?
Selected source-linked reading notes, not the complete literature or a pooled conclusion.
Human · Abstract reviewedCan fat mass fall while lean mass increases?
48 weeks; IV bimagrumab every 4 weeks, with diet and exercise counseling in both groups.
At 48 weeks, fat mass changed by −20.5% with bimagrumab versus −0.5% with placebo; lean mass changed by +3.6% versus −0.8%.
Limits & adverse findings: 75 adults with type 2 diabetes and overweight or obesity were randomized; 58 completed. This was not a GLP combination trial and does not establish preserved strength. The report analyzed treatment completers, which can affect interpretation. The abstract provides limited adverse-event detail.
Open primary source · Read interpretation separatelyExplore outcomes for this compound- Uses & research
Uses have not been independently checked for this profile. Browse the original studies to see the conditions and populations investigated.
- Known half-life
No source-verified value in this profile yet. A treatment schedule or duration of an effect is not a drug half-life.
Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.- Evidence & important limits
A catalog entry does not establish effectiveness, safety or approval. Study findings and quality appraisal remain separate.
Safety & evidence boundaries
Source-specific information, not a personal safety clearance or monitoring plan.
A compound-specific safety synthesis is not available here yet. Lack of listed adverse effects does not establish safety.
Human study: The report analyzed treatment completers, which can affect interpretation. The abstract provides limited adverse-event detail. Source
Explore safety questions by system
These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.
Interactions, rare harms, long-term effects and reversibility require separate evidence. Do not infer they are absent when the sources here do not address them.
Identity, names & formulations
Canonical compound: Bimagrumab · bimagrumab
No additional aliases recorded.
Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.
Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.
Understand the evidence types
Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.
- Randomized human trials
- Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
- Controlled human studies
- Use a comparison group; allocation and confounding still matter.
- Prospective human research
- Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
- Observational human research
- Describes associations. Confounding can explain differences.
- Case reports and series
- Useful for unusual events and safety signals, not reliable rates or effect sizes.
- Animal research
- Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
- Cell and tissue research
- Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
- Mechanistic and computational evidence
- Helps explain or predict a pathway; predictions need experimental and clinical testing.
- Anecdotal reports
- Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.
Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.